AstraZeneca Investor Day Presentation Deck

Overall survival Subgroup analysis Subgroups All patients Sex Race Region ECOG PS at baseline Primary tumor location Disease status Disease classification PD-L1 expression <65 ≥65 Female Male Asian Non-Asian Asia Rest of the world 0 1 ICC ECC GBC Initially unresectable Recurrent Locally advanced Metastatic TAP ≥1% TAP <1% 0.1 0.5 1.5 1 Hazard ratio (95% CI) Favors durvalumab + Gem Cis Favors placebo + GemCis 36 Cl, confidence interval; ECC, extrahepatic cholangiocarcinoma; ECOG, Eastern Cooperative Oncology Group; GBC, gallbladder cancer; GemCis, gemcitabine and cisplatin; ICC, intrahepatic cholangiocarcinoma; OS, overall survival; PD- L1, programmed cell death ligand-1; PS, performance status; TAP, tumor area positivity. 2 Hazard ratio (95% CI) 0.80 (0.66-0.97) 0.80 (0.61-1.04) 0.79 (0.60-1.04) 0.82 (0.62-1.08) 0.78 (0.60-1.01) 0.73 (0.57-0.94) 0.89 (0.66-1.19) 0.72 (0.56-0.94) 0.89 (0.66-1.19) 0.90 (0.68-1.20) 0.72 (0.56-0.94) 0.76 (0.58-0.98) 0.76 (0.49-1.19) 0.94 (0.65-1.37) 0.84 (0.69-1.03) 0.56 (0.32-0.96) 0.49 (0.26-0.88) 0.83 (0.68-1.02) 0.79 (0.61-1.00) 0.86 (0.60-1.23) B

View entire presentation